> top > docs > PMC:7781431 > spans > 17108-18405 > annotations

PMC:7781431 / 17108-18405 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
493 6-11 Gene denotes GPR18 Gene:2841
494 153-158 Gene denotes GPR18 Gene:2841
495 233-238 Gene denotes GPR18 Gene:2841
496 520-525 Gene denotes GPR18 Gene:2841
497 582-587 Gene denotes GPR18 Gene:2841
498 720-725 Gene denotes GPR18 Gene:2841
499 785-788 Gene denotes CB1 Gene:1268
500 790-793 Gene denotes CB2 Gene:1269
501 799-804 Gene denotes GPR55 Gene:9290
502 1054-1059 Gene denotes GPR18 Gene:2841
503 1116-1120 Gene denotes EBI2 Gene:1880
504 281-301 Chemical denotes N-arachidonylglycine MESH:C465623
505 303-308 Chemical denotes NAGly MESH:C465623
506 311-321 Chemical denotes anandamide MESH:C078814
507 359-369 Chemical denotes anandamide MESH:C078814
508 397-417 Chemical denotes abnormal-cannabidiol MESH:C479832
509 419-426 Chemical denotes Abn-CBD MESH:C479832
510 876-903 Chemical denotes n-arachidonoyl ethanolamine MESH:C557222
511 905-908 Chemical denotes AEA MESH:C557222
512 911-934 Chemical denotes 2-arachidonoyl glycerol MESH:C094503
513 936-940 Chemical denotes 2-AG MESH:C094503
514 943-966 Chemical denotes Δ9-tetrahydrocannabinol MESH:D013759
515 968-974 Chemical denotes Δ9-THC MESH:D013759
516 982-1010 Chemical denotes arachidonoylcyclopropylamide
517 1012-1016 Chemical denotes ACPA
518 700-712 Disease denotes inflammation MESH:D007249
519 1175-1208 Disease denotes Epstein-Barr virus (EBV) infected MESH:D020031

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T168 0-5 Sentence denotes GPR18
T169 6-104 Sentence denotes GPR18 was discovered as a receptor for RvD2 through GPCR-β-arrestin-based screening (Chiang et al.
T170 105-173 Sentence denotes 2015), and the receptor was referred to as DRV2/GPR18 (Chiang et al.
T171 174-187 Sentence denotes 2017, 2019a).
T172 188-239 Sentence denotes Besides, several other ligands activate DRV2/GPR18.
T173 240-555 Sentence denotes These include endogenous ligands such as N-arachidonylglycine (NAGly), anandamide, a metabolite of the endocannabinoid anandamide, synthetic ligands such as abnormal-cannabidiol (Abn-CBD), and O-1918, a partial agonist, which can be used as a pharmacological tool to inhibit DRV2/GPR18 signalling (Offertaler et al.
T174 556-574 Sentence denotes 2003; Kohno et al.
T175 575-581 Sentence denotes 2006).
T176 582-659 Sentence denotes GPR18 is abundantly expressed in PMNs, monocytes and macrophages (Wang et al.
T177 660-666 Sentence denotes 2014).
T178 667-1033 Sentence denotes In addition to the resolution of inflammation, while GPR18 has low structural similarity to the cannabinoid receptors CB1, CB2, and GPR55, it responds to endogenous and synthetic cannabinoid ligands including n-arachidonoyl ethanolamine (AEA), 2-arachidonoyl glycerol (2-AG), Δ9-tetrahydrocannabinol (Δ9-THC), and, arachidonoylcyclopropylamide (ACPA) (McHugh, 2012).
T179 1034-1297 Sentence denotes Also interestingly, GPR18 is structurally very similar to EBV-induced receptor 2 (EBI2), whose expression is increased more than 20 times in Epstein-Barr virus (EBV) infected cells, and is a GPCR receptor clustered together in the 13q32 (Rosenkilde et al., 2006).